LightCycler gyrA mutation assay (GAMA) identifies heterogeneity in GyrA in Salmonella enterica serotypes Typhi and Paratyphi A with decreased susceptibility to ciprofloxacin
- 1 December 2003
- journal article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 22 (6) , 622-625
- https://doi.org/10.1016/j.ijantimicag.2003.05.005
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Detection of decreasedin vitro susceptibility to ciprofloxacin in Salmonella enterica serotypes Typhi and Paratyphi AJournal of Antimicrobial Chemotherapy, 2001
- Decreased Susceptibility to Ciprofloxacin inSalmonella entericaserotype Typhi, United KingdomEmerging Infectious Diseases, 2001
- Use of a LightCycler gyrA Mutation Assay for Rapid Identification of Mutations Conferring Decreased Susceptibility to Ciprofloxacin in Multiresistant Salmonella enterica Serotype Typhimurium DT104 IsolatesJournal of Clinical Microbiology, 2001
- Ciprofloxacin-resistant Salmonella typhi and treatment failureThe Lancet, 1999
- Mechanisms of fluoroquinolone resistanceDrug Resistance Updates, 1999
- Role of mutation in the gyrA and parC genes of nalidixic-acid-resistant salmonella serotypes isolated from animals in the United KingdomJournal of Antimicrobial Chemotherapy, 1998
- Molecular Epidemiology of Antibiotic Resistance Genes in Multiresistant EpidemicSalmonella typhimuriumDT 104Microbial Drug Resistance, 1998
- Salmonella typhimurium gyrA mutations associated with fluoroquinolone resistanceAntimicrobial Agents and Chemotherapy, 1995
- Identification of DNA Gyrase A Mutations in Ciprofloxacin-Resistant Isolates ofSalmonella typhimuriumfrom Men and Cattle in GermanyMicrobial Drug Resistance, 1995
- Ciprofloxacin resistance in Salmonella paratyphi AJournal of Antimicrobial Chemotherapy, 1994